1. **Standing business**
   1.1. Welcome & apologies
   1.2. Declaration of potential or actual Conflict of Interest
   1.3. Correspondence
   1.4. Report from the Secretariat

2. **Reviews of existing LSDP medicines**
   **TRANCHE 1** – review of **final reports**
   2.1. imiglucerase (Cerezyme®), velaglucerase (VPRIV®) and taliglucerase (Elelyso®) for treatment of Gaucher disease

   **TRANCHE 2** – review of **final reports**
   2.2. eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria
   2.3. idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis type II
   2.4. alglucosidase alfa (Myozyme®) for treatment of Pompe disease

   **TRANCHE 3** – review of **draft reports**
   2.5. laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
   2.6. galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
   2.7. nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

3. **Applications for new LSDP medicines**

4. **Other business**